Eramet SA (ERA)
Euronext Paris · France · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 35.32 |
|---|---|
| 52-week range | 35.32 – 88.20 |
| Return, 1 month / 3 months | −18.6% / −17.6% |
| Return, 1 year / 3 years | −40.3% / −43.8% |
| Trend | Below its 200-day average |
| RSI (14) | 27 |
| Volatility (1 year) | 58.6% |
| Worst drawdown (1 year) | -59.4% |
| Average daily value traded | 1.20M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Eramet is a French mining and metallurgy group based in Paris. It extracts and processes metals and mineral sands, including manganese, nickel and titanium minerals, through mining operations in several countries. Its alloys and metallurgy businesses make high-performance steels and superalloys for aerospace, energy and defence customers, while other activities supply the chemicals and construction industries. The group serves industrial customers around the world through mining, processing and metal transformation operations.
The shares are listed on the Euronext Paris in France under the code ERA, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Eramet SA (ERA) trades on the Euronext Paris in France. It last closed at EUR 35.32 on 19 October 2026.
Its price-based Market X-Ray is 31 out of 100 (a weak price profile), ranking 498 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 40.3% and over the last three months it fell 17.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 15 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -32.8% | ||
| From 52-week high | -59.4% | ||
| Momentum | 22 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -17.6% | ||
| 6-month return | -36.8% | ||
| 12-month return, skipping the last month | -26.6% | ||
| Stability (higher is calmer) | 25 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 58.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -59.4% | ||
| Liquidity | 80 · Strong | Trades actively. | |
| Average daily value traded | 1.20M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −18.8% |
|---|---|
| 1 month | −18.6% |
| 3 months | −17.6% |
| 6 months | −36.8% |
| 1 year | −40.3% |
| 3 years | −43.8% |
| 5 years | −45.0% |
Signals
| 50-day / 200-day average | 44.32 / 52.54 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.02 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jun 2025 | EUR 0.1500 |
| 4 Jun 2024 | EUR 1.5000 |
| 26 May 2023 | EUR 3.5000 |
| 3 Jun 2022 | EUR 2.5000 |
| 29 May 2019 | EUR 0.6000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.